PMCB PharmaCyte Net earnings per share growth this year

The year-over-year change in earnings per share demonstrates the business stability of PharmaCyte Biotech (PMCB) within the safe haven jurisdiction of the US. This trend is confirmed by the metric value of 0.00. Growth is supported by the unique Cell-in-a-Box system for localized tumor targeting. Revenues will be based on the commercialization of live-cell encapsulation technologies for the therapy of solid neoplasms.

PharmaCyte (PMCB) Earnings growth in current year: for the period 07/04/2022 - 11/10/2026

Analytical breakdowns and data insights for company pharmacyte.com (PMCB)

- stock value and consensus price forecast:

Market Price PharmaCyte Biotech, Inc.|PMCB - Price Target Chart

- market capitalization data:

Market Valuation PharmaCyte Biotech, Inc.|PMCB - Enterprise Value

- company book value details:

Book Value per Share PharmaCyte Biotech|PMCB - Book Capitalization|Market Cap to Net Assets Ratio pharmacyte.com|PMCB - Company Total Assets

- debt burden and liquidity indicators:

All Debt to Shareholders' Equity Ratio PharmaCyte Biotech|PMCB - Long-Term Debt to Equity|Current Liabilities to Equity PharmaCyte Biotech, Inc.|PMCB - Company Aggregate Debts|Debt to Net Assets Ratio PharmaCyte Biotech, Inc.|PMCB - Company Long-Term Debts|Company Short-Term Debts PharmaCyte Biotech|Intermediate Coverage Ratio pharmacyte.com

- earnings and market multiples details:

PMCB - Company Net Income|Future Profit PharmaCyte Biotech|PMCB - P/E Multiple|Forward P/E Multiple PharmaCyte Biotech, Inc.|PMCB - PEG Multiple|Enterprise Value to EBITDA Ratio PharmaCyte Biotech, Inc.|PMCB - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months PharmaCyte Biotech|PMCB - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months pharmacyte.com|PMCB - Earnings growth in current year|Expected net earnings per share growth next year PharmaCyte Biotech

Fundamental valuation:PharmaCyte (PMCB)

Year-over-year earnings per share (EPS) dynamics are critical for assessing the issuer's financial stability. This indicator measures the percentage deviation of current EPS from the value of the same period last year, reflecting the actual efficiency of the business capitalization. For PharmaCyte Biotech (PMCB), current annual EPS growth serves as a marker of the company's ability to overcome biomanufacturing scaling challenges and FDA trial costs.

Direct competitors

Earnings per share growth rate in current year TriSalus (TLSI)|Earnings per share growth in current year RenovoRx Corp